Phosphodiesterase inhibitors: new opportunities for the treatment of asthma.
Phosphodiesterase inhibitors: new opportunities for the treatment of asthma.
复制标题
磷酸二酯酶抑制剂:治疗哮喘的新机会。
作者:
T. Torphy;B. Undem
Theophylline has been a mainstay in the treatment of asthma for over 50 years. Its therapeutic value stems from a combination of antiinflammatory and bronchodilator activities in addition to its ability to increase diaphragmatic contractility.14 Although the pharmacological effects of theophylline have been studied extensively both in the laboratory and in the clinic, the molecular mechanisms responsible for its activity in asthma remain ill defined. In fact, several cellular activities probably contribute to its action, including cyclic nucleotide phosphodiesterase inhibition,' 5 adenosine receptor antagonism,6 stimulation of catecholamine release,7 and a poorly understood ability to increase the number and activity of suppressor T lymphocytes.8 Of theophylline's many activities, phosphodiesterase inhibition may be the most important. Hypothetically, at least two therapeutically beneficial effects could result from inhibition of phosphodiesterase activity and the consequent rise in intracellular adenosine 3',5'-monophosphate (cAMP) or guan-
登录
查看更多内容
DOI:
10.1073/pnas.81.13.3978
发表时间:
1984
影响因子:
11.1
作者:
White,JR;Ishizaka,T;Ishizaka,K;Sha'afi,R
通讯作者:
Sha'afi,R
DOI:
--
发表时间:
1986
期刊:
The Journal of pharmacology and experimental therapeutics
影响因子:
--
作者:
Rossing,TH;Drazen,JM
通讯作者:
Drazen,JM
DOI:
10.1111/1523-1747.ep12272486
发表时间:
1985
期刊:
The Journal of investigative dermatology
影响因子:
--
作者:
Cooper,KD;Kang,K;Chan,SC;Hanifin,JM
通讯作者:
Hanifin,JM
DOI:
10.1073/pnas.83.17.6660
发表时间:
1986
影响因子:
11.1
作者:
Macphee,CH;Harrison,SA;Beavo,JA
通讯作者:
Beavo,JA
DOI:
10.1016/0091-6749(86)90086-2
发表时间:
1986
期刊:
The Journal of allergy and clinical immunology
影响因子:
--
作者:
Nielson,CP;Crowley,JJ;Cusack,BJ;Vestal,RE
通讯作者:
Vestal,RE